397 related articles for article (PubMed ID: 26825707)
1. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
[TBL] [Abstract][Full Text] [Related]
2. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.
Albeituni S; Verbist KC; Tedrick PE; Tillman H; Picarsic J; Bassett R; Nichols KE
Blood; 2019 Jul; 134(2):147-159. PubMed ID: 31015190
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
7. Alleviating the storm: ruxolitinib in HLH.
La Rosée P
Blood; 2016 Mar; 127(13):1626-7. PubMed ID: 27034417
[TBL] [Abstract][Full Text] [Related]
8. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis.
Humblet-Baron S; Franckaert D; Dooley J; Bornschein S; Cauwe B; Schönefeldt S; Bossuyt X; Matthys P; Baron F; Wouters C; Liston A
J Allergy Clin Immunol; 2016 Jul; 138(1):200-209.e8. PubMed ID: 26947179
[TBL] [Abstract][Full Text] [Related]
9. IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.
Humblet-Baron S; Franckaert D; Dooley J; Ailal F; Bousfiha A; Deswarte C; Oleaga-Quintas C; Casanova JL; Bustamante J; Liston A
J Allergy Clin Immunol; 2019 Jun; 143(6):2215-2226.e7. PubMed ID: 30578871
[TBL] [Abstract][Full Text] [Related]
10. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.
Rothman JA; Das R; Teachey DT; Paessler ME; Nichols KE
Pediatr Blood Cancer; 2011 Dec; 57(7):1239-43. PubMed ID: 21681935
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
13. ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.
Rood JE; Rao S; Paessler M; Kreiger PA; Chu N; Stelekati E; Wherry EJ; Behrens EM
Blood; 2016 Jan; 127(4):426-35. PubMed ID: 26518437
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
[TBL] [Abstract][Full Text] [Related]
15. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.
Ghosh S; Carmo M; Calero-Garcia M; Ricciardelli I; Bustamante Ogando JC; Blundell MP; Schambach A; Ashton-Rickardt PG; Booth C; Ehl S; Lehmberg K; Thrasher AJ; Gaspar HB
J Allergy Clin Immunol; 2018 Sep; 142(3):904-913.e3. PubMed ID: 29355678
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
[TBL] [Abstract][Full Text] [Related]
17. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11.
Sepulveda FE; Debeurme F; Ménasché G; Kurowska M; Côte M; Pachlopnik Schmid J; Fischer A; de Saint Basile G
Blood; 2013 Jan; 121(4):595-603. PubMed ID: 23160464
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation.
Tsoukas P; Rapp E; Van Der Kraak L; Weiss ES; Dang V; Schneider C; Klein E; Picarsic J; Salcedo R; Stewart CA; Canna SW
Blood; 2020 Nov; 136(19):2162-2174. PubMed ID: 32589707
[TBL] [Abstract][Full Text] [Related]
20. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis.
Johnson TS; Terrell CE; Millen SH; Katz JD; Hildeman DA; Jordan MB
J Immunol; 2014 Jan; 192(1):84-91. PubMed ID: 24259502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
